Lentiviral Vector (LVV) Lot Release Package

Discover the Lentiviral Vector Lot Release Package offered by WuXi Advanced Therapies, a leading company in bioanalytical testing for cell and gene therapies. This comprehensive package includes a range of assays to ensure the quality and safety of the vector, including tests for titer, potency, transgene sequence, sterility, bioburden, mycoplasma, adventitious agents, residuals, and general characteristics. All testing is conducted in compliance with cGMP standards, guaranteeing the highest level of quality.

With over 20 years of experience, WuXi Advanced Therapies has supported over 140 clients in the cell and gene therapy field. Our new state-of-the-art facility, Rouse 400 or R400, located in Philadelphia, spans 140,000 square feet and is solely dedicated to our testing business. This facility has successfully met regulatory requirements from reputable organizations such as the EMA, TGA, Health Canada, and FDA, ensuring that your therapy meets the highest standards of safety and efficacy.

We are not only committed to providing exceptional testing services but also offer lot release and target patient population services. Our team of project managers and scientific experts are dedicated to providing top-notch customer support, ensuring a seamless experience for their clients. Learn how our Lentiviral Vector Lot Release Package can assist you in achieving your cell and gene therapy goals.